BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28605477)

  • 1. MerTK as a therapeutic target in glioblastoma.
    Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
    Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
    Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
    PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
    DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
    Clin Cancer Res; 2017 Mar; 23(6):1481-1492. PubMed ID: 27649555
    [No Abstract]   [Full Text] [Related]  

  • 4. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
    Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
    J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
    Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
    Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
    Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MerTK activity is not necessary for the proliferation of glioblastoma stem cells.
    Hoque M; Wai Wong S; Recasens A; Abbassi R; Nguyen N; Zhang D; Stashko MA; Wang X; Frye S; Day BW; Baell J; Munoz L
    Biochem Pharmacol; 2021 Apr; 186():114437. PubMed ID: 33571503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme.
    Wang Y; Moncayo G; Morin P; Xue G; Grzmil M; Lino MM; Clément-Schatlo V; Frank S; Merlo A; Hemmings BA
    Oncogene; 2013 Feb; 32(7):872-82. PubMed ID: 22469987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.
    Eom H; Kaushik N; Yoo KC; Shim JK; Kwon M; Choi MY; Yoon T; Kang SG; Lee SJ
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):87-95. PubMed ID: 29553850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
    Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
    Front Immunol; 2021; 12():637053. PubMed ID: 34108959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.
    Su YT; Butler M; Zhang M; Zhang W; Song H; Hwang L; Tran AD; Bash RE; Schorzman AN; Pang Y; Yu G; Zamboni WC; Wang X; Frye SV; Miller CR; Maric D; Terabe M; Gilbert MR; Earp Iii HS; Wu J
    Neurooncol Adv; 2020; 2(1):vdaa065. PubMed ID: 32642716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
    J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
    Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
    Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.
    She Y; Xu X; Yu Q; Yang X; He J; Tang XX
    Respir Res; 2023 Apr; 24(1):118. PubMed ID: 37120511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting Microglial Functions for the Treatment of Glioblastoma.
    Dello Russo C; Lisi L; Tentori L; Navarra P; Graziani G; Combs CK
    Curr Cancer Drug Targets; 2017; 17(3):267-281. PubMed ID: 27528361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury.
    DeBerge M; Yeap XY; Dehn S; Zhang S; Grigoryeva L; Misener S; Procissi D; Zhou X; Lee DC; Muller WA; Luo X; Rothlin C; Tabas I; Thorp EB
    Circ Res; 2017 Sep; 121(8):930-940. PubMed ID: 28851810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
    Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
    J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.
    Zeiner PS; Preusse C; Golebiewska A; Zinke J; Iriondo A; Muller A; Kaoma T; Filipski K; Müller-Eschner M; Bernatz S; Blank AE; Baumgarten P; Ilina E; Grote A; Hansmann ML; Verhoff MA; Franz K; Feuerhake F; Steinbach JP; Wischhusen J; Stenzel W; Niclou SP; Harter PN; Mittelbronn M
    Brain Pathol; 2019 Jul; 29(4):513-529. PubMed ID: 30506802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.